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Examination of urinary decoy cells (DCs) is a useful screening 
test for the detection of polyomavirus (PV) replication. DC shed­
ding may precede or it is concurrently present with PV viremia 
and virus­induced interstitial nephritis.1 The presence of DC, 
however, is not specific for the detection of renal parenchymal 
injury. DC is positive in up to 20% of stable renal allograft re­
cipients. Quantitative polymerase chain reaction (PCR) tests of 
urine and plasma are performed at some institutions as a single 
or an adjunctive procedure.2­4 But these tests are expensive and 
their results usually come later than cytology. In addition to in­
creased risk for PV nephropathy, PV activation is associated with 
increased risk for acute rejection.5 We have speculated that the 
amount of DCs can be a rough estimate of PV activation and 
used as a marker for immunomodulation. We therefore explored 
its significance in persistent shedding, PV nephropathy and acute 
rejection. 
MATERIALS AND METHODS
During a period ranging from January 2003 to December 
2011, a total of 1,956 urine samples were collected for DC test­
ing in 652 renal transplant recipients. Of these, 88 renal allograft 
patients who had DCs detected at least once in four or more urine 
samples (n=601), served as the DC shedding group. One hun­
dred forty­two patients who had no DCs in four or more urine 
samples (n=734) served as the control group. The urinary DC 
test was routinely done on 1, 3, 6, 9, and 12 months after trans­
plant. If DCs were present, urine cytology was repeated at the 
next visit. After one year, the duration of urinary DC test be­
came irregular. In our series of patients, there was a variability 
in its duration. That is, the duration of urinary DC test was less 
than two consecutive years in 78.4% of total patients. In addi­
tion, it was more than two years in 21.6% of patients of the DC 
shedding group and 5.6% of patients of the control group.
The presence of DCs was originally reported as negative or 
no DCs, a few (1­3 DCs/10 high power field [HPF] in routine 
smear slides or in cytospin slide), several (4­9 DCs/10 HPF in 
routine smear slides or in cytospin slide) and many DCs (≥10 
DCs/10 HPF in routine smear slides or in cytospin slide).6 In 
the current study, we classified cases with a few and several DCs 
into the low­grade (LG) shedding group and those with many 
DCs detected at least once during the study into the high­grade 
(HG) shedding group (Fig. 1). If DCs were suspected to be pres­
ent, but not confirmed, an immunocytochemistry for SV­40 
large T antigen (1 :100, room temperature, 32 minutes, Cal­
biochem, Cambridge, MA; Ventana, Tucson, AZ, USA) was 
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performed (Fig. 2). Urinary PV DNA replication was examined 
by quantitative real­time PCR in 35 patients of the HG shed­
ding group and nine patients of the LG shedding group. Plas­
ma PV DNA replication was examined by quantitative real­
time PCR in 33 patients of the HG shedding group and seven 
patients of the LG shedding group. The indications for renal al­
lograft biopsies were serum creatinine elevation, proteinuria of 
≥1 g/24 hr or persistent microscopic hematuria. Thirty­two 
renal allograft biopsies were performed from 88 DC positive 
patients, which were compared with 42 biopsies from 142 pa­
tients of the control group. The biopsy results were also com­
pared with the DC data. PV nephropathy was diagnosed by re­
nal biopsy when tubular epithelial cells with characteristic viral 
inclusion bodies showed SV­40 immunoreactivity. Statistical 
analysis was done with the Chi­square method. 
RESULTS
In the current study, 88 DC­positive patients who were as­
signed to the DC shedding group were classified into the HG 
shedding group (n=51) and the LG shedding group (n=37). 
Urinary DCs first appeared within three months in 29.5%, be­
tween three to six months in 23.9%, between six months to 
one year in 35.2% and more than one year post­transplant in 
11.4% of our series of patients. DC shedding frequently waxed 
and waned. Sustained shedding was defined by the presence of 
DCs during a consecutive period of more than three months, 
and it occurred in 66.7% of patients of the HG shedding group 
and 18.9% of patients of the LG shedding group. Sustained shed­
ding was significantly more prevalent in patients of the HG 
group as compared with their LG counterparts (p<0.0001). 
Fifteen patients (29.4%) of the HG shedding group had inter­
mittent secretion of DCs for more than one year and two patients 
did for more than three years. But only three patients (8.1%) of 
the LG shedding group had secretion of DCs for more than one 
year. At the latest follow­up, there was a persistent presence of 
DCs in 21 patients (41.2%) of the HG shedding group and four 
patients (10.8%) of the LG shedding group. The number of 
DCs was decreased in eight patients of the HG shedding group 
and two patients of the LG group and it was increased in two 
patients of the HG shedding group and one patient of the LG 
group (Table 1). 
Quantitative real­time PCR was positive with a range of 
132,000­6,150,000,000 copies/mL in urine samples collected 
from 18 of 35 patients of the HG shedding group and one of 
nine patients of the LG shedding group. Plasma PCR was posi­
tive with a range of 12,200­593,000 copies/mL in three of 33 
patients of the HG shedding group, but negative in patients of 
the LG shedding group. A diagnosis of PV nephropathy was 
made in seven patients of the HG group within a median peri­
od of 17 months (range, 4 to 28 months) post­transplant. Of 
the six patients with PV nephropathy, for whom the plasma 
Table 1. Comparison between the HG shedding group and the LG 
one
HG LG
Sustained shedding 34 (66.7) 7 (18.9) 
Intermittent DC secretion of more than 1 yr 15 (29.4) 3 (8.1)
Persistently present DCs at the latest follow-up 21 (41.2) 4 (10.8)
Urine PCR positive 18/35 1/9
Plasma PCR positive 3/33 0/7
Values are presented as number (%).
HG, high-grade; LG, low-grade; DC, decoy cells; PCR, polymerase chain 
reaction.
Fig. 1. Voided urine cytology shows many decoy cells displaying 
nuclear enlargement, high N/C ratio and basophilic ‘ground-glass’ 
intranuclear inclusion with marginated chromatin. 
Fig. 2. Decoy cells show a strong nuclear positivity for the SV-40 
immunostain.
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and urine PCR were performed, five and two were positive for 
urinary and plasma PCR, respectively. The prevalence of PV 
nephropathy was higher in the HG shedding group than the 
LG shedding group (p=0.019). 
Immunosuppression was decreased in seven patients who were 
diagnosed with PV nephropathy. In nine patients of the HG 
shedding group who were not diagnosed with PV nephropathy, 
the dose of mycophenolate was lowered or its treatment was 
discontinued. DCs disappeared in three patients on 3, 4, and 7 
months after modulation. The number of DCs was decreased in 
four patients, but they were persistently present in two patients. 
In six patients with viruria or viremia, confirmed on the real­
time PCR, however, the renal function was stable without im­
munomodulation.
Acute rejection episodes were proven on biopsy in seven pa­
tients of the HG shedding group and in 12 patients of the con­
trol group. Five patients of the HG shedding group shed DCs 
prior to the onset of acute rejection. Plasma PCR for PV was 
positive in one patient at the onset of acute rejection and it be­
came positive after treatment of acute rejection in one patient 
(Table 2). In addition, there was no significant difference in the 
prevalence of acute rejection between the HG shedding group 
and the control group (p=0.875). 
DISCUSSION
The current study demonstrated that the degree of urinary 
DCs was correlated with sustained shedding, urinary PCR and 
development of PV nephropathy. The duration of urinary DC 
shedding was longer in the HG shedding group than LG shed­
ding group (shedding of more than one year, 29.4% vs. 8.1%; 
sustained shedding of more than three consecutive months, 
66.7% vs. 18.9%). Urinary PCR was positive in 51.4% of pa­
tients of the HG shedding group and 11.1% of patients of the 
LG shedding group. In addition, plasma PCR was positive in 
17.6% of patients of the HG shedding group who were posi­
tive for urine PCR. Furthermore, plasma PCR was negative in 
one patient of the LG shedding group who was positive for urine 
PCR. All the seven patients with PV nephropathy experienced 
HG shedding of DCs. 
In our screening program of PV, the urinary DC test was per­
formed at a 1­ and then 3­month interval during the first post­
transplant year. Most of the DC shedders could be detected dur­
ing this period as urinary DCs first appeared within a year post­
transplant in 88.6% of total patients. But the duration of uri­
nary DC test remains uncertain. Hirsch et al.7 recommended 
that it be done as a routine screening procedure at a 3­month 
interval during the first two years of post­transplant. Singh et 
al.8 recommended that it be more frequently for the first six 
months and then on a yearly basis. In the current study, urinary 
DC test was done at a 3­month interval for more than two years 
in 5% of patients of the LG shedding group and 33.3% of pa­
tients of the HG shedding group. But there were two patients 
who developed PV nephropathy more than two years post­trans­
plant. Furthermore, at the latest follow­up, there was a persis­
tent presence of DCs in more than 40% of patients of the HG 
shedding group. It would therefore be valid to perform urinary 
DC test at least on a yearly basis after the first year post­trans­
plant in patients who have experienced more than a single epi­
sode of HG shedding.
Another thing to consider is immunomodulation. It has been 
reported that the allograft function is preserved following re­
duced immunosuppression even in presumptive cases of PV ne­
phropathy.9 There was a gradual decrease in immunosuppres­
sion in nine patients of the HG shedding group. But there were 
two patients where DCs were not decreased in number or dis­
appeared. By contrast, DCs were decreased or disappeared with­
out reduction of immunosuppression in a substantial percent­
age of patients, which was clearly in patients of the LG shed­
ding group. In six patients with viruria or viremia, confirmed 
Table 2. Results of the urinary DC and urinary/plasma PV PCR test 
in patients with acute rejection
(mo) -36       -12      -6
Time of diagnosis of 
acute rejection
-3                        +3   +6     +12    +36
Case 1 
  Urine 
  plasma
                    HG    LG
            - -   +    +    +
                   -
                   +
Case 2 
  Urine 
  plasma
                   HG HG
               -  + + +-
               -           -
           + -  +    +
              -   -    +
    LG
    +++-
    ++  -
Case 3 
  Urine 
  plasma
              LG                 LG           HG
                              +      + + +  +             +  +++  +++  +
                                -     + + +  +             +  - - +     -      -
Case 4 
  Urine 
  plasma
                         -
                         -
  LG           HG
                  +
                  -
Case 5 
  Urine 
  plasma
                 HG
             --    + -    -
                    -
                 ---
Case 6 
  Urine 
  plasma
                          HG
                    ---  -   -
                    ---  -   -
   -
   -
Case 7 
  Urine 
  plasma
HG       LG
-+          +             +
--          -              -
                LG
       +         -
        -         -
DC, decoy cells; PV PCR, polyomavirus polymerase chain reaction.
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on the real­time PCR, the renal function was stable without 
immunomodulation. The viral load is the most important fac­
tor for producing PV nephropathy. It remains obscure, however, 
who can benefit from the decreased immunosuppression. It is 
therefore necessary to identify viral genotypes and to determine 
host’s immune reaction to the virus, both of which may play a 
role in tissue injury.10
Acute rejection is frequently associated in allograft patients 
with PV nephropathy.11 Our results showed that the prevalence 
of acute rejection was relatively higher after DC shedding as 
compared with prior to it. But there was no difference in the 
prevalence of acute rejection between the DC shedding group 
and the control group. This indicates that DC shedding is not a 
predictor of acute rejection. Acute rejection may be present con­
currently with PV nephropathy. Renal biopsy should therefore 
be considered in patients with graft dysfunction accompanied 
by HG DC shedding.
Limitation of the current study originated from a variability 
in the methods of urine sampling. The study was conducted us­
ing either routine smear slides or cytospin slides to estimate the 
amount of DCs for PV activation. We think this variability might 
not have a serious impact on the results since there were numer­
ous DCs in most patients of the HG shedding group with no 
respect to the methods of urine sampling.
In conclusion, our results indicate that shedding of ≥10 
DCs/10 HPF is a clinically significant indicator for sustained 
shedding and risk for PV nephropathy but it is not a predictor 
of acute rejection. This implies that a continuous monitoring 
would be needed for patients with HG shedding even after a 
transient clearance of DCs.
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